Advanced Medical Equipment & Technology

Fukuda Denshi Co Ltd to issue mid-year dividend for FY 2015

Fukuda Denshi Co Ltd:To issue a mid-year dividend of 50 yen per share to all the shareholders of record as of Sep. 30, for FY ending March 2015.Payment date Dec. 8.Says latest dividend forecast was 45 yen per share.

Thursday, 30 Oct 2014 11:00pm EDT

Alphatec Holdings Inc sees FY 2014 guidance towards lower end of prior range

Alphatec Holdings Inc:Expects FY 2014 consolidated revenues to come in towards the lower end of the previously established guidance range of $208 to $212 mln.Expects FY 2014 Non GAAP Adjusted EBITDA to come in towards the lower end of the previously established guidance range of $30 to $33 mln.FY...

Thursday, 30 Oct 2014 04:09pm EDT

IRIDEX Corp gives Q4 2014 revenue guidance

IRIDEX Corp:Expects to achieve revenue of $10.9 to $11.2 mln for the Q4 2014.

Thursday, 30 Oct 2014 04:09pm EDT

Greatbatch Inc raises low end of prior FY 2014 revenue guidance; raises FY 2014 EPS guidance

Greatbatch Inc:Raises FY 2014 revenue and adjusted diluted earnings per share guidance range to $695 million - $705 million and $2.32 - $2.38 per share, respectively.FY 2014 revenue of $700 million and EPS of $2.32 - Thomson Reuters I/B/E/S.

Thursday, 30 Oct 2014 04:08pm EDT

GenMark Diagnostics Inc raises FY 2014 revenue guidance

GenMark Diagnostics Inc:Says FY 2014 revenue to exceed $29.0 mln.FY 2014 revenue of $27.8 mln - Thomson Reuters I/B/E/S.

Thursday, 30 Oct 2014 04:06pm EDT

Castlight Health Inc gives Q4 2014 mixed guidance; raises FY 2014 revenue and EBIT guidance; reaffirms FY 2014 EPS guidance

Castlight Health Inc:Expects Q4 2014 revenue to be in the range of $12.8 million to $13.2 million.Expects Q4 2014 non-GAAP operating loss (EBIT) to be in the range of ($19.6) million to ($20.6) million.Expects Q4 2014 non-GAAP basic and diluted loss per share (EPS) to be about ($0.22) to...

Thursday, 30 Oct 2014 04:01pm EDT

Fluidigm Corp narrows FY 2014 revenue guidance to a range in line with analysts' estimates

Fluidigm Corp:Now expects FY 2014 revenue to be between $114 and $117 million versus prior guidance of $112 to $118 million.Organic revenue is projected to be between $95 and $96 million an increase of 33 to 35 pct over FY 2013, compared to prior guidance of 32 to 35 pct.FY 2014 revenue of $116...

Thursday, 30 Oct 2014 04:00pm EDT

Nexstim prospectus supplemented

Nexstim Ltd:Says Nexstim Plc's prospectus supplemented with indicative price range lowered, number of offer shares increased and subscription period extended.Maximum number of offer shares that may be issued in offering (excluding additional 431,034 offer shares in case of oversubscription) is...

Thursday, 30 Oct 2014 11:54am EDT

Harvard Bioscience Inc raises FY 2014 outlook

Harvard Bioscience Inc:Increased its financial guidance from Feb. 27, to reflect its acquisitions of Multi Channel Systems MCS and Triangle BioSystems.Expects FY 2014 revenues to be about $107-$108 mln, or an about 2- 3 pct increase compared to FY 2013's revenues.Expects FY 2014 non-GAAP diluted...

Thursday, 30 Oct 2014 07:31am EDT

Abiomed Inc raises low end of prior FY 2015 revenue guidance to a range above analysts' estimates

Abiomed Inc:Increases lower end of its FY 2015 revenue guidance with the new range of $209 million to $212 million from the original range of $205 million to $212 million.FY 2015 revenue of $208 million - Thomson Reuters I/B/E/S.

Thursday, 30 Oct 2014 07:04am EDT

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.

Analyst Research

Report Title Price
Provider: Renaissance Capital
$92.00
Provider: Renaissance Capital
$92.00
Provider: Renaissance Capital
$92.00
Provider: Renaissance Capital
$92.00
Provider: Renaissance Capital
$92.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.